Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease.
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
09
03
2021
revised:
11
08
2021
accepted:
24
08
2021
pubmed:
4
9
2021
medline:
10
5
2022
entrez:
3
9
2021
Statut:
ppublish
Résumé
Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.
Identifiants
pubmed: 34478878
pii: S1542-3565(21)00921-6
doi: 10.1016/j.cgh.2021.08.041
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Gastrointestinal Agents
0
Tumor Necrosis Factor-alpha
0
Rituximab
4F4X42SYQ6
vedolizumab
9RV78Q2002
Types de publication
Journal Article
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1483-e1487Informations de copyright
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.